Peptides: The FDA Opens a 'Pandora's Box'
The Week's editors compile reactions to last month's FDA advisory panel vote recommending that six previously restricted peptides be permitted for compounding sale, opening with Tom Bartlett's framing in The Atlantic that the country is headed "over a peptide cliff" — highlighting that these six compounds were banned from pharmacy dispensing back in 2023 over unresolved efficacy and safety concerns, concerns the panel's own vote did not resolve so much as set aside.
This is a summary. The reporting is The Week — Opinion Roundup's, and the link below goes to the original article.